🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca173 Eli Lilly and Company150 Merck Sharp & Dohme LLC116 AbbVie112 Novartis Pharmaceuticals107
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Florida

4401 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
By invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
DrugTreprostinil
United Therapeutics
Phase 3
1,850
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-09-06
Active, closed
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
NCT05481879Myotonic Dystrophy Type 1 (DM1)
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 1/2
127
California, Florida, Indiana, Iowa, Missouri, New York, Texas, Virginia
2022-09-05
Recruiting
TVMR With the INNOVALVE System Trial - Early Feasibility Study
NCT04919980Mitral Valve Regurgitation (Degenerative or Functional)
Edwards Lifesciences
Not applicable
85
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey
2022-09-01
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697Advanced Solid Tumors
DrugsIpilimumab·Nivolumab·Pembrolizumab
ModernaTX, Inc.
Phase 1/2
361
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Missouri
2022-09-01
Recruiting
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
NCT05422911Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
DrugsApalutamide·Abiraterone acetate·Enzalutamide
Sun Pharmaceutical Industries Limited
Phase 2
192
California, Florida, Michigan, Missouri, New York, North Carolina, Oregon, Pennsylvania
2022-08-31
Active, closed
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer
DrugsPalazestrant·Atirmociclib·Alpelisib·Everolimus
Olema Pharmaceuticals, Inc.
Phase 1
190
Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota
2022-08-31
Recruiting
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT05281471Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsOlvimulogene nanivacirepvec·Pegylated liposomal doxorubicin·Nab-paclitaxel·Cisplatin
Genelux Corporation
Phase 3
186
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Michigan
2022-08-31
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05271409Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Hoffmann-La Roche
Phase 3
132
Alabama, California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan
2022-08-30
Recruiting
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103Advanced Cancer, Metastatic Cancer
DrugPembrolizumab
Qurient Co., Ltd.
Phase 1/2
130
Arizona, California, Florida, Illinois, Minnesota, New Jersey, Texas
2022-08-30
Active, closed
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
NCT05456880Sickle Cell Disease
Beam Therapeutics Inc.
Phase 1/2
15
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2022-08-30
Recruiting
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296Endometrial Adenocarcinoma
Acrivon Therapeutics
Phase 2
350
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2022-08-29
Recruiting
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT05455619HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
SynDevRx, Inc.
Phase 1/2
52
California, Florida, Illinois, Michigan, Ohio, Pennsylvania, Tennessee, Texas
2022-08-26
Active, closed
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
iTeos Therapeutics
Phase 2
36
Arkansas, Florida
2022-08-26
Active, closed
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222NASH, Cirrhosis, Liver
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 3
845
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2022-08-26
Active, closed
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Biogen
Phase 2
416
Arizona, California, Colorado, Florida, Hawaii, Massachusetts, New York, North Carolina
2022-08-24
Recruiting
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
NCT05156983Coagulation Disorder
Takeda
Phase 3
440
Arkansas, California, Colorado, Florida, New Jersey, North Carolina, Ohio, Oklahoma
2022-08-24
Active, closed
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
NCT05445323Friedreich Ataxia, Cardiomyopathy, Secondary
Lexeo Therapeutics
Phase 1/2
8
California, Florida, Minnesota
2022-08-24
Active, closed
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
NCT04839705Wide Neck Bifurcation Intracranial Aneurysms
Microvention-Terumo, Inc.
Not applicable
195
Florida, Hawaii, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts
2022-08-24
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, New York
2022-08-23
Active, closed
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
NCT05536973Neovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc.
Phase 2
69
Arizona, California, Colorado, Connecticut, Florida, Hawaii, Michigan, Mississippi
2022-08-23
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2/3
1,856
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-08-22
Active, closed
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
NCT05516992Lumbar Degenerative Disc Disease
Spine BioPharma, Inc
Phase 3
417
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kansas
2022-08-19
Active, closed
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
NCT05451810Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
DrugEpcoritamab
Genmab
Phase 2
184
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-08-17
Active, closed
GammaTile and Stupp in Newly Diagnosed GBM
NCT05342883Glioblastoma
GT Medical Technologies, Inc.
Phase 4
61
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Michigan
2022-08-17
Active, closed
Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes
NCT05506423Open Angle Glaucoma
Iantrek, Inc.
Observational
300
California, Florida, Georgia, Maryland, Nevada, New Jersey, New York, Pennsylvania
2022-08-17
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341HIV-1-infection
DrugsBIC/LEN FDC·Bictegravir·Lenacapavir
Gilead Sciences
Phase 2/3
689
California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey
2022-08-16
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705Obstructive Hypertrophic Cardiomyopathy
DrugMavacamten
Bristol-Myers Squibb
Observational
1,700
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-08-16
Active, closed
MiSight 1 Day Safety Post-Approval Study
NCT05285527Myopia
CooperVision, Inc.
Not applicable
2,400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Indiana
2022-08-15
Recruiting
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer
Day One Biopharmaceuticals, Inc.
Phase 1/2
360
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2022-08-15
Recruiting
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858Brain Tumor, Non Small Cell Lung Cancer
DrugsCemiplimab·Atezolizumab·Nivolumab·Pembrolizumab
InSightec
Phase 3
30
Arizona, California, Florida, Maryland, North Carolina, Oregon, Rhode Island, Virginia
2022-08-12
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
DrugsCeralasertib·Durvalumab
AstraZeneca
Phase 2
194
California, Florida, Maryland, Tennessee
2022-08-11
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Arizona, California, Colorado, Florida, Illinois, Kansas, Louisiana, Maryland
2022-08-10
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 3
412
Alabama, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho
2022-08-10
Active, closed
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776Iliofemoral; Thrombosis
Mercator MedSystems, Inc.
Phase 2
60
Connecticut, Florida, Illinois, Louisiana, Maryland, New York, North Carolina, Ohio
2022-08-08
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
California, Colorado, Florida, Kansas, Michigan, New Jersey, New York, Oregon
2022-08-05
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
506
California, Florida, Georgia, Illinois, Kansas, Massachusetts, New Mexico, New York
2022-08-04
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus
Genentech, Inc.
Phase 3
373
Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-08-03
Active, closed
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
NCT05297448Hepatic Encephalopathy
DrugRifaximin SSD
Bausch Health Americas, Inc.
Phase 3
466
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-08-03
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
DrugsSavolitinib·Osimertinib·Pemetrexed·Cisplatin
AstraZeneca
Phase 3
341
Florida, Hawaii, New Jersey, New York, Tennessee
2022-08-03
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
DrugIDRX-42
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Florida, Illinois, Massachusetts, Missouri, New York, Oregon, Pennsylvania, Texas
2022-08-03
Recruiting
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell
DrugSTP938
Step Pharma, SAS
Phase 1/2
180
Colorado, Florida, New York
2022-08-03
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
DrugsD3S-001·Pemetrexed·Cisplatin·Carboplatin
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
California, Colorado, Florida, Michigan, Tennessee, Texas
2022-08-03
Active, closed
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584Type 2 Diabetes
DrugTirzepatide
Eli Lilly and Company
Phase 4
780
Alabama, California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky
2022-08-01
Active, closed
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas
HUYABIO International, LLC.
Phase 1
44
California, Florida, Michigan, Missouri, Ohio
2022-08-01
Active, closed
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
NCT05566041Carcinoma, Small Cell Lung
DrugsRRx-001·Cisplatin/carboplatin·Etoposide
EpicentRx, Inc.
Phase 3
292
Florida, Kansas
2022-08-01
Recruiting
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
NCT05303467Glioblastoma Multiforme, Recurrent Glioblastoma
Boston Scientific Corporation
Phase 1
36
Alabama, California, Florida, Illinois, Maryland, Missouri, New York, Texas
2022-07-30
Active, closed
Noninterventional Study Evaluating Parkinson's Disease Diary Use
NCT05363046Parkinson's Disease
BlueRock Therapeutics
Observational
194
Arizona, California, Colorado, Florida, Illinois, Kansas, Kentucky, Massachusetts
2022-07-29
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595Advanced or Metastatic Colorectal Cancer
DrugsAmivantamab·Leucovorin·Irinotecan·Oxaliplatin
Janssen Research & Development, LLC
Phase 1/2
225
Alabama, California, District of Columbia, Florida, Maryland, Michigan, Mississippi, New York
2022-07-29
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsSacituzumab Govitecan·Nab-paclitaxel·Gemcitabine·Carboplatin
Gilead Sciences
Phase 3
443
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-07-25
Active, closed
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
NCT05352828Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
DrugsBendamustine·Nivolumab·Fludarabine
Tessa Therapeutics
Phase 1
15
California, Florida, North Carolina, Texas
2022-07-25
Active, closed
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420Idiopathic Pulmonary Fibrosis
DrugsDeupirfenidone·Pirfenidone
PureTech
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Indiana, Kansas, North Carolina
2022-07-22
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsGolimumab·JNJ-78934804·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-07-22
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsIbrutinib·Pirtobrutinib
Loxo Oncology, Inc.
Phase 3
737
California, Florida, Louisiana, Maryland, Montana, Pennsylvania, South Carolina, Tennessee
2022-07-22
Active, closed
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
NCT05496686Uveal Melanoma, Metastatic
Modulation Therapeutics, Inc.
Phase 1
16
Florida
2022-07-21
Active, closed
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma
Xencor, Inc.
Phase 2
170
Arizona, California, Colorado, Delaware, Florida, Georgia, Michigan, Nevada
2022-07-21
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsSacituzumab Govitecan·Nab-paclitaxel·Gemcitabine·Carboplatin
Gilead Sciences
Phase 3
623
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2022-07-20
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Florida, Georgia, Nebraska, New York
2022-07-20
Recruiting
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
NCT05265273Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
12
Arizona, California, Colorado, Florida, Kansas, Michigan, Pennsylvania
2022-07-20
Recruiting
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 1/2
53
California, Florida, Kansas, Kentucky, New York, Ohio, Pennsylvania, Wisconsin
2022-07-20
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DrugsDB-1305/BNT325·Pumitamig
DualityBio Inc.
Phase 1/2
1,123
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Michigan, Nevada
2022-07-19
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsPhesgo·Giredestrant·Paclitaxel
Hoffmann-La Roche
Phase 3
922
Arizona, California, Florida, Maryland, New York, Tennessee, Texas, Washington
2022-07-18
Recruiting
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
NCT06426628Pulmonary Nodule, Solitary, Lung Cancer
Veracyte, Inc.
Observational
2,400
Connecticut, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland, Massachusetts
2022-07-18
Active, closed
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885Multiple Myeloma
DrugAnitocabtagene-autoleucel
Kite, A Gilead Company
Phase 2
136
Arizona, Arkansas, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-07-15
Recruiting
Safety and Effectiveness of the HIT Reverse HRS
NCT05357378Degenerative Joint Disease, Osteoarthritis, Hip, Avascular Necrosis of Hip, Traumatic Arthropathy-Hip
Hip Innovation Technology
Not applicable
288
Florida, Maryland, New Jersey, Ohio
2022-07-15
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
452
Alabama, California, Florida, Georgia, Louisiana, Michigan, Nevada, New York
2022-07-14
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
DrugsMepolizumab·Depemokimab
GlaxoSmithKline
Phase 3
163
Colorado, Florida, Minnesota, New York, North Carolina, Pennsylvania
2022-07-14
Active, closed
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672Melanoma
DrugsFianlimab·Cemiplimab·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,546
California, Florida, Ohio, Tennessee
2022-07-14
Active, closed
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
NCT05392114Hereditary Angioedema
DrugDonidalorsen
Ionis Pharmaceuticals, Inc.
Phase 3
154
Arizona, California, Florida, Kansas, Massachusetts, Michigan, Missouri, North Carolina
2022-07-13
Recruiting
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
NCT05488340Urinary Tract Infections
DrugTMP/SMX
Locus Biosciences
Phase 2
318
California, Florida, Massachusetts, Missouri, North Carolina
2022-07-13
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
Dren Bio
Phase 1/2
200
Alabama, California, Connecticut, Florida, Massachusetts, New York, Ohio, Pennsylvania
2022-07-13
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Atezolizumab
Novartis Pharmaceuticals
Phase 1/2
55
Florida, Georgia, Kentucky, Missouri, New Jersey, Ohio, Pennsylvania
2022-07-13
By invitation
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
NCT05481827Age Related Macular Degeneration (AMD)
Gyroscope Therapeutics Limited
Phase 2
225
California, Colorado, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts
2022-07-12
Active, closed
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446Metastatic Colorectal Cancer
DrugsEncorafenib·Pemetrexed·Pembrolizumab
Pfizer
Phase 2
108
Arizona, Florida, Tennessee, Texas
2022-07-11
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
609
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2022-07-08
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Alaska, Arkansas, California, Florida, Georgia, Idaho, Maryland, Massachusetts
2022-07-08
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
DrugsGoserelin·Tamoxifen·Anastrozole·Ribociclib
Novartis Pharmaceuticals
Phase 4
134
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-07-07
Active, closed
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
NCT05573984Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod
PYC Therapeutics
Observational
50
California, Florida, Michigan, Oregon, Texas
2022-07-07
Active, closed
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
DrugTaldefgrobep alfa
Biohaven Pharmaceuticals, Inc.
Phase 3
269
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2022-07-06
Active, closed
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634Myositis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2
36
Arizona, California, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan
2022-07-05
Active, closed
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922Solid Tumors
DrugsRibociclib·Olaparib·Palbociclib·Fulvestrant
Incyte Corporation
Phase 1
291
California, Colorado, Connecticut, Florida, Georgia, New York, North Carolina, Pennsylvania
2022-07-05
Active, closed
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
DrugsPF-07799933·Binimetinib·Midazolam·Leucovorin
Pfizer
Phase 1
103
Arkansas, Colorado, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio
2022-07-05
Recruiting
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
NCT04565795Ureteral Diseases
Adva-Tec
Not applicable
87
Arizona, California, Florida, Ohio
2022-07-01
Recruiting
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
NCT04918173Congenital Antithrombin Deficiency
Octapharma
Phase 3
38
District of Columbia, Florida, Illinois, New York, North Carolina
2022-07-01
Recruiting
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141Acute Respiratory Distress Syndrome, ARDS
Direct Biologics, LLC
Phase 3
970
Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Iowa, Maryland
2022-07-01
Active, closed
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613Erosive Esophagitis
DrugNexium
AstraZeneca
Phase 3
53
Alabama, California, Florida, Indiana, Louisiana, New York, Ohio, Wisconsin
2022-07-01
Active, closed
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 1
160
Arizona, California, Florida, Michigan, Texas, Virginia
2022-06-30
Recruiting
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
NCT04042844Lumbar Disc Disease
BioRestorative Therapies
Phase 2
99
Alabama, California, Colorado, Florida, New York, North Carolina, Ohio, Oklahoma
2022-06-30
Active, closed
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT05456425Pterygium
Cloudbreak Therapeutics, LLC
Phase 3
660
Alabama, Arizona, California, Florida, Kentucky, Nevada, South Dakota, Texas
2022-06-30
Active, closed
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
Phase 3
529
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Missouri
2022-06-30
Recruiting
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064Schizophrenia, Bipolar I Disorder
DrugsOLZ/SAM·Olanzapine
Alkermes, Inc.
Phase 3
220
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-06-30
Recruiting
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
NCT05040178Hyperammonemia, Methylmalonic Acidemia, Propionic Acidemia
DrugCarglumic Acid
RECORDATI GROUP
Observational
20
District of Columbia, Florida, Illinois, Indiana, New York
2022-06-30
Recruiting
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357Glaucoma, Open-Angle, Ocular Hypertension
Amneal Pharmaceuticals, LLC
Phase 3
168
California, Florida, Georgia, Tennessee, Texas, Wyoming
2022-06-29
Active, closed
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
DrugsNab-paclitaxel /m^2·Relacorilant
Corcept Therapeutics
Phase 3
381
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2022-06-29
Active, closed
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
DrugBezuclastinib
Cogent Biosciences, Inc.
Phase 2
237
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-06-27
Active, closed
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553Myopia
CooperVision, Inc.
Not applicable
900
Alabama, California, Florida, Illinois, Indiana, Kansas, Massachusetts, Minnesota
2022-06-25
Recruiting
Comprehensive Outcomes for After Cancer Health
NCT05349227Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
Pack Health
Not applicable
625
Florida, Massachusetts, Nebraska, New York, Ohio, Texas
2022-06-23
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2022-06-23
Active, closed
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT05346354Neuromyelitis Optica Spectrum Disorder
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 2/3
12
District of Columbia, Florida, Massachusetts, North Carolina, Pennsylvania
2022-06-23
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
DrugsMontelukast·Diphenhydramine·Isatuximab·Methylprednisolone
Sanofi
Phase 3
531
Colorado, Florida, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina
2022-06-23
Active, closed
MOTUS Total Joint Replacement Investigational Device Exemption Study
NCT05438719Lumbar Spine Degeneration
3Spine
Not applicable
158
California, Colorado, Florida, Kentucky, Louisiana, Minnesota, New York, North Carolina
2022-06-23
Rows per page Showing 3201–3300 of 4401
Previous 31 32 33 34 35 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/florida?page=33

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4,401 of those studies with a site in Florida.

How many clinical trials are recruiting in Florida?

2,364 of the 4,401 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 103 have not yet opened recruitment, 1,825 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.